Compare Amgen, Inc. (AMGN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Rigetti Computing Inc — how do they compare? Amgen, Inc. trades at $441.03 (market cap $236.98B), while Rigetti Computing Inc trades at $11.58 (market cap $4.02B). The key difference: Amgen, Inc. is far larger — about 59× Rigetti Computing Inc's market cap, and Amgen, Inc. pays a 2.3% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amgen, Inc. for 72 Days and Rigetti Computing Inc for 37 Days on average.
| AMGN | RGTI | |
|---|---|---|
Market Cap | $236.98B | $4.02B |
Volume | 2,263,159 | 10,136,350 |
Sector | Health | Technology |
52-Week High | $444.12 | $44.27 |
52-Week Low | $291.16 | $11.66 |
Typical Hold Time | 72 Days | 37 Days |
Enterprise Value | $280.30B | $3.64B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $438.94, up 3.29% with strong bullish momentum near 52-week highs. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $6.29 versus $5.62, and maintains impressive profitability with 22.95% net margin and 91.47% ROE. Recent positive Phase 3 results for dazodalibep in Sjögren's disease highlight pipeline strength, while technical indicators signal bullish moving averages despite overbought RSI conditions.
Amgen presents a compelling investment case with consistent earnings beats and strong cash flow generation, though elevated valuation ratios (P/E 27.26) and high debt levels warrant caution. The consensus price target of $402.21 suggests limited upside from current levels, while competitive pressures in biotech and acquisition-related debt pose medium-term risks to shareholder returns.
Rigetti Computing (RGTI) trades at $11.66, down 0.09% with bearish technical signals despite strong analyst support. The company shows minimal revenue growth ($7M in 2025, $13M in 2026) but deep losses (-$216M net income in 2025) and negative margins. Recent news highlights quantum computing sector momentum, with RGTI advancing hybrid quantum-HPC partnerships and benefiting from industry developments.
The stock faces significant fundamental challenges with unsustainable valuation metrics and negative profitability, though analyst consensus remains strongly bullish with a $22.50 price target. Key risks include execution challenges in commercializing quantum technology and cash burn requiring continued financing. The technical picture suggests near-term weakness despite oversold RSI conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
